These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 29373924

  • 1. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
    Ighani A, Georgakopoulos JR, Zhou LL, Walsh S, Shear N, Yeung J.
    J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 4. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [Abstract] [Full Text] [Related]

  • 5. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D.
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB.
    Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
    [Abstract] [Full Text] [Related]

  • 7. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A, Levi E.
    J Drugs Dermatol; 2017 Dec 01; 16(12):1240-1245. PubMed ID: 29240859
    [Abstract] [Full Text] [Related]

  • 8. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.
    J Drugs Dermatol; 2013 Aug 01; 12(8):888-97. PubMed ID: 23986162
    [Abstract] [Full Text] [Related]

  • 9. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M.
    J Dermatol; 2018 Nov 01; 45(11):1345-1348. PubMed ID: 30168880
    [Abstract] [Full Text] [Related]

  • 10. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M, Walsh S, Shear N.
    J Cutan Med Surg; 2016 Jul 01; 20(4):313-6. PubMed ID: 26848145
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P.
    J Eur Acad Dermatol Venereol; 2013 Mar 01; 27(3):e376-83. PubMed ID: 23030767
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, Day RM, Chen R, Shah K, Ferrándiz C, Cather JC.
    J Am Acad Dermatol; 2017 Aug 01; 77(2):310-317.e1. PubMed ID: 28416342
    [Abstract] [Full Text] [Related]

  • 13. Apremilast in psoriasis - a prospective real-world study.
    Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter L.
    J Eur Acad Dermatol Venereol; 2018 Feb 01; 32(2):254-259. PubMed ID: 28925560
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, Goncalves J, Levi E, Callis Duffin K.
    J Drugs Dermatol; 2017 Aug 01; 16(8):801-808. PubMed ID: 28809995
    [Abstract] [Full Text] [Related]

  • 17. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.
    Ohata C, Ohyama B, Kuwahara F, Katayama E, Nakama T.
    J Dermatolog Treat; 2019 Jun 01; 30(4):383-386. PubMed ID: 30221571
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Real-World Experience With Apremilast in Treating Psoriasis.
    Mayba JN, Gooderham MJ.
    J Cutan Med Surg; 2017 Jun 01; 21(2):145-151. PubMed ID: 27846617
    [Abstract] [Full Text] [Related]

  • 20. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
    J Am Acad Dermatol; 2016 Jul 01; 75(1):99-105. PubMed ID: 27021239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.